{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:02:28Z","timestamp":1792422148865,"version":"4.5.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral agents used to treat renal anemia in chronic kidney disease (CKD). While their erythropoietic effects are well-documented, the potential consequences of HIF-mediated vascular endothelial growth factor (VEGF) activation remain uncertain. This meta-analysis aimed to evaluate the effect of HIF-PHI therapy on VEGF levels and the risk of VEGF-related adverse outcomes in CKD patients.<\/jats:p>\n                  <jats:p>Methods We systematically analyzed 34 randomized controlled trials (RCTs) including 26 trials reporting VEGF levels and additional data on cancer, diabetic retinopathy, peripheral edema, and thrombosis. Subgroup analyses were performed based on drug type, treatment duration, dialysis status, trial phase, and comparator type.<\/jats:p>\n                  <jats:p>Results HIF-PHI treatment was associated with a modest but significant increase in VEGF levels (SMD = 0.23; 95% CI: 0.07\u20130.39) and a reproducible increase in peripheral edema risk (log RR = 0.22; 95% CI: 0.09\u20130.35). No significant associations were found for cancer, diabetic retinopathy, or thrombosis. Dialysis status moderated VEGF response, with greater elevation observed in dialysis-dependent patients.<\/jats:p>\n                  <jats:p>Conclusion HIF-PHIs modestly increase VEGF expression, with peripheral edema as the most consistent adverse signal. However, no evidence of oncologic or retinal harm was found in the short term. Long-term surveillance is recommended.<\/jats:p>","DOI":"10.1093\/joneph\/aajag065","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:44:24Z","timestamp":1775216664000},"page":"1129-1143","source":"Crossref","is-referenced-by-count":1,"title":["Impact of HIF-prolyl hydroxylase inhibitors on VEGF expression and vascular adverse events in chronic kidney disease: a meta-analysis of 34 randomized controlled trials"],"prefix":"10.1093","volume":"39","author":[{"given":"Seyed Mahdi","family":"Montazer","sequence":"first","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences , Sari, Mazandaran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Asadi","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences , Sari, Mazandaran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Taghipour","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences , Sari, Mazandaran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshia","family":"Rajabi","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences , Sari, Mazandaran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshak","family":"Shabanian","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences , Sari, Mazandaran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Daraei","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences , Sari, Mazandaran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bahmani","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Bay","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences , Sari, Mazandaran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Karimi","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences , Sari, Mazandaran ,","place":["Iran"]},{"name":"Nephrology Research Center, School of Medicine, Mazandaran University of Medical Sciences , Sari, Mazandaran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026101002224625600_aajag065-B1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/ndt\/gfad250","article-title":"Anaemia in CKD\u2014treatment standard","volume":"39","author":"Macdougall","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026101002224625600_aajag065-B2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1159\/000518072","article-title":"Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study","volume":"52","author":"Yamamoto","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026101002224625600_aajag065-B3","doi-asserted-by":"publisher","first-page":"100677","DOI":"10.1016\/j.xkme.2023.100677","article-title":"Iron-deficiency anemia in CKD: a narrative review for the kidney care team","volume":"5","author":"Hain","year":"2023","journal-title":"Kidney Med"},{"key":"2026101002224625600_aajag065-B4","doi-asserted-by":"publisher","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents","volume":"8","author":"Portol\u00e9s","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026101002224625600_aajag065-B5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/mnh.0000000000000813","article-title":"Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?","volume":"31","author":"Macdougall","year":"2022","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"2026101002224625600_aajag065-B6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/13543784.2020.1777276","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?","volume":"29","author":"Souza","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"2026101002224625600_aajag065-B7","doi-asserted-by":"publisher","first-page":"Cd013751","DOI":"10.1002\/14651858.CD013751.pub2","article-title":"Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease","volume":"8","author":"Natale","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026101002224625600_aajag065-B8","doi-asserted-by":"publisher","first-page":"1296702","DOI":"10.3389\/fphar.2023.1296702","article-title":"Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses","volume":"14","author":"Ren","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026101002224625600_aajag065-B9","doi-asserted-by":"publisher","first-page":"sfae051","DOI":"10.1093\/ckj\/sfae051","article-title":"Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia","volume":"17","author":"Nakanishi","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026101002224625600_aajag065-B10","doi-asserted-by":"publisher","first-page":"172532","DOI":"10.1016\/j.ejphar.2019.172532","article-title":"JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-\u03b1 protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor","volume":"859","author":"Fukui","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"2026101002224625600_aajag065-B11","doi-asserted-by":"publisher","first-page":"e47430","DOI":"10.7759\/cureus.47430","article-title":"Safety and efficacy of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoietin-stimulating agents in treating anemia in renal patients (with or without dialysis): a meta-analysis and systematic review","volume":"15","author":"Damarlapally","year":"2023","journal-title":"Cureus"},{"key":"2026101002224625600_aajag065-B12","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.3390\/jcm11102722","article-title":"Efficacy of different doses of daprodustat for anemic non-dialysis patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"11","author":"Fadlalmola","year":"2022","journal-title":"J Clin Med"},{"key":"2026101002224625600_aajag065-B13","doi-asserted-by":"publisher","first-page":"1406588","DOI":"10.3389\/fphar.2024.1406588","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis","volume":"15","author":"Ren","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026101002224625600_aajag065-B14","doi-asserted-by":"publisher","first-page":"1131516","DOI":"10.3389\/fendo.2023.1131516","article-title":"Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: a network meta-analysis","volume":"14","author":"Yang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026101002224625600_aajag065-B15","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.18632\/aging.204611","article-title":"A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease","volume":"15","author":"Chen","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"2026101002224625600_aajag065-B16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026101002224625600_aajag065-B17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"2026101002224625600_aajag065-B18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026101002224625600_aajag065-B19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026101002224625600_aajag065-B20","doi-asserted-by":"publisher","first-page":"e39471","DOI":"10.1371\/journal.pone.0039471","article-title":"Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses","volume":"7","author":"Thorlund","year":"2012","journal-title":"PLoS One"},{"key":"2026101002224625600_aajag065-B21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989x.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"key":"2026101002224625600_aajag065-B22","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2026101002224625600_aajag065-B23","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026101002224625600_aajag065-B24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101002224625600_aajag065-B25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101002224625600_aajag065-B26","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/asn.2019060623","article-title":"Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026101002224625600_aajag065-B27","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ekir.2021.04.003","article-title":"Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026101002224625600_aajag065-B28","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026101002224625600_aajag065-B29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/asn.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026101002224625600_aajag065-B30","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026101002224625600_aajag065-B31","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1681\/asn.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2026101002224625600_aajag065-B32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects","volume":"45","author":"Akizawa","year":"2017","journal-title":"Am J Nephrol"},{"key":"2026101002224625600_aajag065-B33","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of Anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101002224625600_aajag065-B34","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101002224625600_aajag065-B35","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"2026101002224625600_aajag065-B36","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101002224625600_aajag065-B37","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101002224625600_aajag065-B38","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1681\/asn.2020091311","article-title":"Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD","volume":"32","author":"Nangaku","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026101002224625600_aajag065-B39","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/ndt\/gfab055","article-title":"Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study","volume":"36","author":"Nangaku","year":"2021","journal-title":"Nephrol Dial Transplant."},{"key":"2026101002224625600_aajag065-B40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000500487","article-title":"Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial","volume":"143","author":"Akizawa","year":"2019","journal-title":"Nephron"},{"key":"2026101002224625600_aajag065-B41","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.ekir.2021.04.037","article-title":"A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026101002224625600_aajag065-B42","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1159\/000517053","article-title":"A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study","volume":"7","author":"Akizawa","year":"2021","journal-title":"Kidney Dis (Basel)"},{"key":"2026101002224625600_aajag065-B43","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.ekir.2021.07.015","article-title":"Molidustat for Japanese patients with renal anemia receiving dialysis","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep."},{"key":"2026101002224625600_aajag065-B44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ckj\/sfy013","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease","volume":"12","author":"Holdstock","year":"2019","journal-title":"Clin Kidney J"},{"key":"2026101002224625600_aajag065-B45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis","volume":"12","author":"Meadowcroft","year":"2019","journal-title":"Clin Kidney J"},{"key":"2026101002224625600_aajag065-B46","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/cjn.16011219","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026101002224625600_aajag065-B47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000513103","article-title":"Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial","volume":"52","author":"Nangaku","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026101002224625600_aajag065-B48","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000523961","article-title":"Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND)","volume":"53","author":"Agrawal","year":"2022","journal-title":"Am J Nephrol"},{"key":"2026101002224625600_aajag065-B49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000523949","article-title":"Desidustat in anemia due to dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-D)","volume":"53","author":"Gang","year":"2022","journal-title":"Am J Nephrol"},{"key":"2026101002224625600_aajag065-B50","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026101002224625600_aajag065-B51","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026101002224625600_aajag065-B52","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv Ther"},{"key":"2026101002224625600_aajag065-B53","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-\u00adcontrolled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026101002224625600_aajag065-B54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2215\/cjn.02510218","article-title":"Effects of molidustat in the treatment of anemia in CKD","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026101002224625600_aajag065-B55","doi-asserted-by":"publisher","first-page":"27004","DOI":"10.31083\/fbl27004","article-title":"HIF-1\u03b1 and VEGF immunophenotypes as potential biomarkers in the prognosis and evaluation of treatment efficacy of atherosclerosis: a systematic review of the literature","volume":"30","author":"Vageli","year":"2025","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2026101002224625600_aajag065-B56","doi-asserted-by":"publisher","first-page":"7707","DOI":"10.1002\/jcb.27120","article-title":"Hypoxia inducible factor-1\u03b1\/vascular endothelial growth factor signaling activation correlates with response to radiotherapy and its inhibition reduces hypoxia-induced angiogenesis in lung cancer","volume":"119","author":"Zhu","year":"2018","journal-title":"J Cell Biochem"},{"key":"2026101002224625600_aajag065-B57","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1210\/clinem\/dgaa538","article-title":"MicroRNA-15b targets VEGF and inhibits angiogenesis in proliferative diabetic retinopathy","volume":"105","author":"Yang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101002224625600_aajag065-B58","doi-asserted-by":"publisher","first-page":"e1004612","DOI":"10.1371\/journal.pcbi.1004612","article-title":"Computational model of MicroRNA control of HIF-VEGF pathway: insights into the pathophysiology of ischem\u00adic\u00a0vascular disease and cancer","volume":"11","author":"Zhao","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"2026101002224625600_aajag065-B59","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1182\/hematology.2024000655","article-title":"Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease","volume":"2024","author":"Haase","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026101002224625600_aajag065-B60","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000537913","article-title":"Exacerbation of diabetic retinopathy following hypoxia-inducible factor-prolyl hydroxylase inhibitor administration: a case report","volume":"15","author":"Ariyoshi","year":"2024","journal-title":"Case Rep Ophthalmol"},{"key":"2026101002224625600_aajag065-B61","doi-asserted-by":"publisher","first-page":"876723","DOI":"10.3389\/fcell.2022.876723","article-title":"WT1: the hinge between anemia correction and cancer development in chronic kidney disease","volume":"10","author":"Lee","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2026101002224625600_aajag065-B62","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.preteyeres.2011.05.001","article-title":"Acute retinal arterial occlusive disorders","volume":"30","author":"Hayreh","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"2026101002224625600_aajag065-B63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/978-981-13-7647-4_10","article-title":"Roles of drug transporters in blood-retinal barrier","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"2026101002224625600_aajag065-B64","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease","volume":"11","author":"Haase","year":"2021","journal-title":"Kidney Int Suppl (2011)"},{"key":"2026101002224625600_aajag065-B65","doi-asserted-by":"publisher","first-page":"2413176","DOI":"10.1155\/2022\/2413176","article-title":"Efficacy and safety of roxadustat in patients with chronic kidney disease: an updated meta-analysis of randomized controlled trials including 6,518 patients","volume":"2022","author":"Lei","year":"2022","journal-title":"Biomed Res Int"},{"key":"2026101002224625600_aajag065-B66","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/SLA.0b013e318162d616","article-title":"Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma?","volume":"247","author":"Ganter","year":"2008","journal-title":"Ann Surg"},{"key":"2026101002224625600_aajag065-B67","author":"Fallo"},{"key":"2026101002224625600_aajag065-B68","doi-asserted-by":"publisher","first-page":"103942","DOI":"10.1016\/j.ebiom.2022.103942","article-title":"Hypoxia and chronic kidney disease","volume":"77","author":"Wang","year":"2022","journal-title":"EBioMedicine."},{"key":"2026101002224625600_aajag065-B69","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1681\/asn.2005070757","article-title":"Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure","volume":"17","author":"Nangaku","year":"2006","journal-title":"J Am Soc Nephrol."},{"key":"2026101002224625600_aajag065-B70","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aaf4405","article-title":"Hypoxic control of metastasis","volume":"352","author":"Rankin","year":"2016","journal-title":"Science"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/6\/1129\/69855324\/aajag065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/6\/1129\/69855324\/aajag065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:22:52Z","timestamp":1791613372000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/6\/1129\/8740351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,7,23]]},"published-print":{"date-parts":[[2026,10,10]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag065","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]}}}